Further funding announced for clinical studies and data investigation
After a year of disruption, clinical research has now restarted and lab-based research is getting back on track. Cure Parkinson’s is delighted to report that it is investing significant funds into research in the first quarter of 2021.
Learn more
The Unifying Challenge
Create your team or sign up as individual, and complete your own unique 100 mile challenge to highlight and support further research into potentially life changing treatments for Parkinson’s. Between 1 – 14 September 2021, join 41 other individuals or teams and aim to cover...
Joyce Cook walks over 300,000 steps for Cure Parkinson’s
On Monday 10 May, 86 year old Joyce Cook from Chorleywood crossed the finish line of her incredible 300,000 step challenge. To mark Parkinson’s Awareness Month, Joyce walked more than 10,000 steps each day for 30 days, beginning on 11 April (World Parkinson’s Day), to…
Something ‘LRRK -ing’ in the data
Over recent years, researchers have been identifying genetic variations associated with an increased risk of developing Parkinson’s. A recent study has thrown further light on the connection between certain genetic risk factors and Parkinson’s progression.
Further support for diabetes treatments for Parkinson’s
A research group in South Korea has published results of their trial which provide further evidence that diabetes treatments can slow down the development of Parkinson’s in people with diabetes.
Important phase 1 trial results for LRRK2 inhibitor drug
This week the biotech company Denali Therapeutics announced the results of a phase 1 clinical trial of their LRRK2 inhibitor drug called ‘DNL151’. Their findings have interesting implications for the Parkinson’s community.